Metformin: a modulator of bevacizumab activity in cancer? A case report

Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic cancer patients treated with bevacizumab may...

Descripción completa

Detalles Bibliográficos
Autores principales: Indraccolo, Stefano, Randon, Giovanni, Zulato, Elisabetta, Nardin, Margherita, Aliberti, Camillo, Pomerri, Fabio, Casarin, Alessandra, Nicoletto, Maria Ornella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Bedside to Bench Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623111/
https://www.ncbi.nlm.nih.gov/pubmed/25607951
http://dx.doi.org/10.1080/15384047.2014.1002366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623111/
https://www.ncbi.nlm.nih.gov/pubmed/25607951
http://dx.doi.org/10.1080/15384047.2014.1002366

Ejemplares similares